YOU ARE HERE: LAT HomeCollections


October 06, 1987

Three announcements in the last week helped propel Rohr Industries 1 7/8 to 34 3/4, according to Irving Katz, director of research for San Diego Securities.

During an interview with Dow Jones, Rohr forecast a 21% increase in annual sales to $800 million. Rohr expects earnings to rise by 34% to 44%.

The company also announced that it would purchase Fairchild's composite bonding center in Hagerstown, Md., for an undisclosed amount. Last week the company filed for $100 million in convertible debentures.

Molecular Biosystems made a new high of 15 1/2 and closed the week up 2 1/8 to 14 1/8 on the announcement that the Food & Drug Administration would treat its Albunex ultrasound contrast imaging agent as a medical device. That classification could ultimately lead to more rapid market approval, Katz said.

Fabulous Inns was up one-half to 4 1/2 as the latest controlling management group offered to purchase all public shares for $6 each.

Good gains were also shown by WD-40, up 1 to 35; Synbiotics, up one to 8 3/4, and, Mycogen, plus three-quarters to 10 1/2. Xscribe, which went public at 8 and dropped to 6 1/2, recovered somewhat to close up three-quarters at 7 1/2.

Cubic Corp. was up seven-eighths to 21 3/4 after telling its story on the Financial News Network.

On the downside, Xytronyx dropped three-quarters to 12 after announcing new financing as it privately placed $500,000 in 8 1/2% convertible notes, convertible at $10 per share.

Video Library was down three-eighths to 3 3/8 in response to adverse articles on the intense competition in the video store industry.

Los Angeles Times Articles